Status:

WITHDRAWN

Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Lead Sponsor:

Sun Yat-sen University

Conditions:

ICC

Metastatic Cancer

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

This study were designed to verify the better method of survival for metastatic ICC. Since the traditional method for metastatic ICC was GEMOX(recommended from NCCN guideline), our previous study fou...

Detailed Description

ICC(Intrahepatic CholangioCarcinoma) patients with metastasis has a short survival time and poor prognosis after diagnosis. Treatment methods was few and far from satisfaction. The treatment recommend...

Eligibility Criteria

Inclusion

  • The diagnosis of ICC
  • With distant metastasis
  • Patients must have at least one tumor lesion that can be accurately measured according to mRECIST criteria.
  • With no previous treatment
  • No Cirrhosis or cirrhotic status of Child-Pugh class A only
  • Not amendable to surgical resection ,local ablative therapy and any other cured treatment
  • The following laboratory parameters:
  • Platelet count ≥ 50,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/ L Serum albumin ≥ 32 g/L ASL and AST ≤ 6 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) \>1,500/mm3

Exclusion

  • Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
  • Known history of HIV
  • History of organ allograft
  • Known or suspected allergy to the investigational agents or any agent given in association with this trial.
  • Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
  • Evidence of bleeding diathesis.
  • Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.

Key Trial Info

Start Date :

May 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2021

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04398927

Start Date

May 1 2020

End Date

February 1 2021

Last Update

February 4 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cancer Center Sun Yat-sen University

Guangzhou, Guangdong, China, 510060